Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7.

Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7.

Yaoqing Chen, Luyang Cao, Maohua Zhong, Yan Zhang, Chen Han, Qiaoli Li, Jingyi Yang, Dihan Zhou, Wei Shi, Benxia He, Fang Liu, Jie Yu, Ying Sun, Yuan Cao, Yaoming Li, Wenxin Li, Deying Guo, Zhijian Cao, Huimin Yan

For over 30 years, HIV/AIDS has wreaked havoc in the world. In the absence of an effective vaccine for HIV, development of new anti-HIV agents is urgently needed. We previously identified the antiviral activities of the scorpion-venom-peptide-derived mucroporin-M1 for three RNA viruses (measles viruses, SARS-CoV, and H5N1). In this investigation, a panel of scorpion venom peptides and their derivatives were designed and chosen for assessment of their anti-HIV activities. A new scorpion venom peptide derivative Kn2-7 was identified as the most potent anti-HIV-1 peptide by screening assays with an EC(50) value of 2.76 µg/ml (1.65 µM) and showed low cytotoxicity to host cells with a selective index (SI) of 13.93. Kn2-7 could inhibit all members of a standard reference panel of HIV-1 subtype B pseudotyped virus (PV) with CCR5-tropic and CXCR4-tropic NL4-3 PV strain. Furthermore, it also inhibited a CXCR4-tropic replication-competent strain of HIV-1 subtype B virus. Binding assay of Kn2-7 to HIV-1 PV by Octet Red system suggested the anti-HIV-1 activity was correlated with a direct interaction between Kn2-7 and HIV-1 envelope. These results demonstrated that peptide Kn2-7 could inhibit HIV-1 by direct interaction with viral particle and may become a promising candidate compound for further development of microbicide against HIV-1.

2012

DOI: 10.1371/journal.pone.0034947

PLoS ONE

Public Library of Science (PLoS)

Science, Medicine

EN